Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · IEX Real-Time Price · USD
1.510
-0.070 (-4.43%)
At close: Jul 2, 2024, 4:00 PM
1.440
-0.070 (-4.64%)
After-hours: Jul 2, 2024, 5:34 PM EDT

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019
Market Capitalization
3854898651,861--
Market Cap Growth
-3.81%-43.52%-53.52%---
Enterprise Value
-86-12881,313-562-411
PE Ratio
--2.08-4.72-7.44--
PS Ratio
5661.153758.6610.22174.77--
PB Ratio
0.640.751.042.00--
P/FCF Ratio
-3.53-2.94-4.46-9.71--
P/OCF Ratio
-3.55-2.98-5.10-14.74--
EV/Sales Ratio
1400.11-7.593.40123.25-72.48-625.15
EV/EBITDA Ratio
-0.460.00-1.74-5.552.813.21
EV/EBIT Ratio
-0.420.00-1.57-5.252.753.17
EV/FCF Ratio
-0.590.01-1.49-6.852.65-17.53
Debt / Equity Ratio
0.090.090.080.07-0.17-0.24
Debt / EBITDA Ratio
-0.27-0.27-0.38-0.28-0.25-0.21
Debt / FCF Ratio
-0.34-0.34-0.33-0.35-0.241.16
Quick Ratio
16.2815.8317.3013.1612.4419.86
Current Ratio
16.5116.0717.5913.4012.5319.97
Asset Turnover
000.090.010.01-
Return on Equity (ROE)
-33.90%-32.70%-21.50%-38.40%103.10%-
Return on Assets (ROA)
-29.70%-28.80%-18.30%-22.60%-28.40%-
Return on Capital (ROIC)
-36.46%-34.70%-20.87%-21.55%87.73%121.56%
Earnings Yield
-59.32%-48.02%-21.17%-13.44%--
FCF Yield
-41.74%-34.05%-22.40%-10.30%--
Buyback Yield / Dilution
-1.87%-1.58%-81.79%-925.18%-144.21%-
Total Shareholder Return
-1.87%-1.58%-81.79%-925.18%-144.21%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).